19-Oct-2026 - Yahoo Finance Bristol-Myers Squibb Seen Beating Q3 Revenue Estimates, RBC Says Bristol-Myers Squibb (BMY) is expected to beat consensus Q3 revenue estimates, driven by stronger-than-expected sales of legacy products Eliquis and Revlimid, as well as growth pr ...
14-Oct-2026 - The Globe and Mail Truist Financial Sticks to Its Buy Rating for Bristol-Myers Squibb (BMY) Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on Bristol-Myers Squibb today and set a price target of $70.00. According to TipRanks, Devarakonda is a 5-star analyst with an ...
19-Oct-2026 - Yahoo Finance Bristol-Myers Squibb Seen Beating Q3 Revenue Estimates, RBC Says Bristol-Myers Squibb (BMY) is expected to beat consensus Q3 revenue estimates, driven by stronger-than-expected sales of legacy products Eliquis and Revlimid, as well as growth pr ...
14-Oct-2026 - The Globe and Mail Truist Financial Sticks to Its Buy Rating for Bristol-Myers Squibb (BMY) Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on Bristol-Myers Squibb today and set a price target of $70.00. According to TipRanks, Devarakonda is a 5-star analyst with an ...
